Management of Abemaciclib‐Associated Adverse Events in Patients with Hormone Receptor‐Positive, Human Epidermal Growth Factor Receptor 2‐Negative Advanced Breast Cancer: Safety Ana...

por Rugo, Hope S., Huober, Jens, García‐Sáenz, José A., Masuda, Norikazu, Sohn, Joo Hyuk, Andre, Valerie A.M., Barriga, Susana, Cox, Joanne, Goetz, Matthew
Publicado 2020

Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups

por Johnston, Stephen, O’Shaughnessy, Joyce, Martin, Miguel, Huober, Jens, Toi, Masakazu, Sohn, Joohyuk, André, Valérie A. M., Martin, Holly R., Hardebeck, Molly C., Goetz, Matthew P.
Publicado 2021

Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer:...

por Goetz, Matthew P., Okera, Meena, Wildiers, Hans, Campone, Mario, Grischke, Eva-Maria, Manso, Luis, André, Valérie A. M., Chouaki, Nadia, San Antonio, Belén, Toi, Masakazu, Sledge, George W.
Publicado 2021

Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2− advanced breast cancer: MONARCH 2 & 3 trials

por Toi, Masakazu, Inoue, Kenichi, Masuda, Norikazu, Iwata, Hiroji, Sohn, Joohyuk, Hae Park, In, Im, Seock‐Ah, Chen, Shin‐Cheh, Enatsu, Sotaro, Turner, P. Kellie, André, Valérie A. M., Hardebeck, Molly C., Sakaguchi, Sachi, Goetz, Matthew P., Sledge, George W.
Publicado 2021

Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1

por Rugo, Hope S., Dieras, Veronique, Cortes, Javier, Patt, Debra, Wildiers, Hans, O’Shaughnessy, Joyce, Zamora, Esther, Yardley, Denise A., Carter, Gebra Cuyun, Sheffield, Kristin M., Li, Li, Andre, Valerie A. M., Li, Xiaohong I., Frenzel, Martin, Huang, Yu-Jing, Dickler, Maura N., Tolaney, Sara M.
Publicado 2020